Pfizer Inc
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
FRSHY China Jinmao Holdings Group Ltd
EQH-C Equitable Holdings Inc
IBTX Independent Bank Group Inc
DLTR Dollar Tree Inc
FRTX Fresh Tracks Therapeutics Inc
PLXS Plexus Corp
YEXT Yext Inc
UPWK Upwork Inc
NEGG Newegg Commerce Inc
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.

Closing Price
$43.79
Day's Change
-0.46 (-1.04%)
Bid
--
Ask
--
B/A Size
--
Day's High
44.34
Day's Low
43.78
Volume
(Average)
Volume:
23,798,610

10-day average volume:
25,315,032
23,798,610

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE

3:05 pm ET November 9, 2022 (Newsfile) Print

New York, New York--(Newsfile Corp. - November 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors ofPfizer Inc.("Pfizer" or the "Company") (NYSE: PFE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Pfizer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On October 26, 2022, Bloomberg reported that Italian authorities are investigating Pfizer for allegedly hiding profits of at least €1.2 billion by transferring money to business units in other countries, including the U.S. and the Netherlands, to avoid taxes. The probe began in February and covers 2017 through 2019.

On this news, Pfizer's stock price fell $0.32 per share, or 0.69%, to close at $45.74 per share on October 27, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/143665

comtex tracking

COMTEX_418490344/2523/2022-11-09T15:05:21

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.